总时间（秒）：36226.92
问答时间（秒）：633.63

```json
{
  "functional_evidence_assessment": []
}
```

```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "C",
          "alt": "G",
          "position": "289"
        },
        "variant_string_id": "Parkin C289G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Cells were treated with CCCP and immunolabeled with anti-Hsp60 to assess mitochondrial function.",
          "judgment": "Yes",
          "reasoning": "The paper defines a disease mechanism related to mitochondrial dysfunction, which is relevant to the Parkin gene's role in mitophagy."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The percentage of cells with overlapping GFP-LC3 and MitoDsRed staining was quantified in cells co-transfected with FLAG-Parkin(WT) and FLAG-Parkin(C289G).",
          "judgment": "Yes",
          "reasoning": "The assay used (quantification of overlapping GFP-LC3 and MitoDsRed staining) is applicable to the disease mechanism as it measures mitophagy, a key function of Parkin.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Experiments were performed with multiple replicates and included both wild-type (FLAG-Parkin(WT)) and mutant (FLAG-Parkin(C289G)) controls.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that multiple replicates were used and includes both wild-type and mutant controls, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study used FLAG-Parkin(WT) as a normal control and FLAG-Parkin(C289G) as the variant of interest.",
          "judgment": "No",
          "reasoning": "The study lacks additional variant controls such as known pathogenic or benign variants, limiting the ability to compare the variant of interest.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study quantifies the incidence of transfected cells with mitochondrial staining in CCCP-treated cells but does not calculate OddsPath.",
          "judgment": "N/A",
          "reasoning": "The study does not provide a statistical analysis sufficient for OddsPath calculation and uses fewer than 10 variant controls.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The Parkin C289G variant shows a functional impact on mitophagy, but the evidence is limited to supporting strength due to insufficient variant controls and lack of statistical analysis for OddsPath."
    }
  ]
}
```

**Note**: The provided answer assumes that the functional evidence aims to demonstrate pathogenicity based on the context of mitophagy dysfunction associated with Parkin mutations. The strength of the evidence was determined as "PS3_supporting" due to the lack of variant controls and statistical analysis for OddsPath.
Based on the text provided, I've extracted information about the Parkin C289G variant and applied the ACMG functional evidence evaluation flowchart.

The assessment concludes that the Parkin C289G variant has functional evidence supporting pathogenicity with a strength of PS3_supporting. This assessment is based on:
1. The clear disease mechanism defined (mitochondrial dysfunction)
2. Appropriate assay used (quantification of overlapping GFP-LC3 and MitoDsRed staining to measure mitophagy)
3. Sufficient basic controls and replicates
4. Limitations in variant controls (only wild-type and the variant of interest, no additional known pathogenic or benign variants)
5. Lack of statistical analysis for OddsPath calculation

This assessment aligns with the ACMG guidelines for functional evidence evaluation.

ed with CCCP (20 mM, 4 h) and immunolabeled with anti-Hsp60 (red). (B) The percentage of cells with overlapping GFP-LC3 and MitoDsRed staining was quantified in cells co-transfected with FLAG-Parkin(WT), FLAG-Parkin(C289G) + myc-HSJ1a(WT) and treated with CCCP (20 mM, 4 h). Error bars: +2 SE, n ¼ 4, * * * P , 0.001. (C) Quantification of the incide

 bars: +2 SE, n ¼ 4, * * * P , 0.001. (C) Quantification of the incidence of transfected cells with mitochondrial staining in cells treated with CCCP (20 mM, 24 h, left bar), CCCP + 3-MA (10 mM, 24 h, right bar). Error bars: +2 SE, n ¼ 4, * P , 0.5.

in and 100 mg/ml streptomycin (Invitrogen). Cells were grown at 378C in 5% (v/v) CO 2 . Transfections using a constant amount of plasmid DNA were performed using Lipofectamine TM and PLUS TM reagents (Invitrogen), according to the manufacturer's protocol.

##Antibodies and reagents
Mouse monoclonal anti-FLAG (M2), mouse monoclonal anti-Hsp60 (LK1) 

Question:

**Instruction:**
You are a highly skilled scientific text analysis and gene variant assessment assistant. Your primary task is to:
1.  **Extract relevant functional evidence details** from the provided scientific paper text for *each variant* mentioned that has functional data.
2.  **Parse variant identification information** to populate the specific fields: "Gene", "Protein Change" (ref, alt, position), and a combined "variant\_string\_id".
3.  **Apply the ACMG functional evidence evaluation flowchart** to the extracted information for each variant.
4.  **Determine the strength of the functional evidence** (PS3 for pathogenic, BS3 for benign) for each variant.
5.  **Output the results in a pyJSON format**, including the step-by-step judgment process and the final strength rating for each variant.

**Output Format:**
Your final output MUST be a JSON object. The top-level key will be `functional_evidence_assessment`. Its value will be an array of objects, where each object represents the assessment for a single variant. Each variant object should have the following structure:

```json
{
  "variant_id": {
    "Gene": "Extracted_Gene_Symbol", // E.g., "EGFR", "CFTR"
    "Protein_Change": {
      "ref": "Extracted_Reference_Amino_Acid", // E.g., "L", "R"
      "alt": "Extracted_Alternate_Amino_Acid", // E.g., "R", "H"
      "position": "Extracted_Amino_Acid_Position" // E.g., "858", "117"
    },
    "variant_string_id": "Gene RefPosAlt" // E.g., "EGFR L858R", "CFTR R117H"
  },
  "functional_evidence_aim": "Pathogenic", // or "Benign", derived from the paper's context of what the functional assay aims to show
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "Quote or concise summary of the relevant text from the paper.",
      "judgment": "Yes", // or "No"
      "reasoning": "Explanation based on extracted info and flowchart logic."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "Quote or concise summary of the relevant text from the paper.",
      "judgment": "Yes", // or "No"
      "reasoning": "Explanation based on extracted info and flowchart logic.",
      "next_step_or_outcome": "Proceed to Step 3" // or "Do not use PS3/BS3"
    }
    // ... (Include all relevant sub-steps taken according to the flowchart,
    //     each with "step_name", "extracted_paper_info", "judgment", "reasoning", and "next_step_or_outcome" if applicable)
  ],
  "final_evidence_strength": {
    "type": "Pathogenic", // or "Benign"
    "strength": "PS3_very_strong" // or "PS3_moderate", "PS3_supporting", "BS3_very_strong", "BS3_moderate", "BS3_supporting", "N/A" if "Do not use PS3/BS3"
  },
  "overall_conclusion": "Brief summary of why this strength was assigned for this variant, referencing key findings."
}
```

**ACMG Functional Evidence Evaluation Flowchart (Reference Standard for LLM's Internal Logic):**

**Step 1: Define the disease mechanism.**
* **Internal Question:** Does the paper clearly define the disease mechanism relevant to the functional assay being described for this variant?
* **Internal Judgment Basis:** Extract explicit statements or strong inferences about the disease's molecular basis and how the gene/protein functions within it.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Question:** Does the *general class* of assay used for this variant (e.g., enzyme activity assay, protein interaction assay, gene expression assay, cell phenotype rescue assay, etc.) effectively model or reflect the disease pathogenesis/mechanism defined in Step 1?
* **Internal Decision Logic:**
    * If **NO**: Then **Do not use PS3/BS3**. (Functional evidence not applicable).
    * If **YES**: Proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Question 1:** Were basic controls included for this assay? Specifically, were *both* "Normal/Negative/Wild type" **AND** "Abnormal/Positive/Null" controls used?
    * **Internal Question 2:** Did the paper explicitly state that multiple replicates were used for the experiments?
    * **Internal Judgment Basis:** Search "Materials and Methods" and "Results" for descriptions of controls (e.g., "wild-type protein," "empty vector," "known loss-of-function mutant," "known gain-of-function mutant") and details on experimental repetition (e.g., "performed in triplicate," "n=3 independent experiments").
    * **Internal Decision Logic (for 3a):**
        * If **NO** (either condition not met): Proceed to Sub-step 3b.
        * If **YES** (both conditions met): Proceed to Sub-step 3c.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Question:** Has the specific instance of the assay been:
        * a) Broadly accepted historically (e.g., standard technique in the field)? **OR**
        * b) Previously validated in other studies (cited)? **OR**
        * c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?
    * **Internal Judgment Basis:** Look for statements on assay novelty, references to prior validation, or mentions of commercial kits/standards.
    * **Internal Decision Logic (for 3b):**
        * If **NO** (all conditions not met): Then **Do not use PS3/BS3**.
        * If **YES** (any condition met): The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Question:** Were variant controls used in the assay for this variant? Specifically, were:
        * Known pathogenic variants used as controls? **OR**
        * Known benign variants used as controls? **OR**
        * Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?
    * **Internal Judgment Basis:** Identify lists of variants used as positive/negative controls and their stated classifications or known status.
    * **Internal Decision Logic (for 3c):**
        * If **NO** (all conditions not met): The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.
        * If **YES** (any condition met): Proceed to Step 4.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Question:** Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays).
    * **Internal Judgment Basis:** Look for mentions of statistical tests, p-values, effect sizes, confidence intervals, or direct calculation/reporting of OddsPath.
    * **Internal Decision Logic (for 4a):**
        * If **NO**: Proceed to Sub-step 4b.
        * If **YES**: Proceed to Sub-step 4c.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Question:** How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?
    * **Internal Judgment Basis:** Count the number of explicitly identified benign and pathogenic control variants used in the assays related to this variant.
    * **Internal Decision Logic (for 4b):**
        * If **10 or less** in total: The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.
        * If **At least 11** in total: The functional evidence strength is **Max PS3_moderate / Max BS3_moderate**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Information:** Extract the OddsPath value calculated in the paper for this variant. If a direct OddsPath is not given but robust statistics are, infer the strength.
    * **Internal Judgment Basis:** Apply ACMG guidelines for OddsPath interpretation (e.g., assuming standard thresholds: PS3: OddsPath > 18.7 = very_strong; OddsPath > 4.3 = moderate; OddsPath > 2.0 = supporting. BS3: OddsPath < 1/18.7 = very_strong; OddsPath < 1/4.3 = moderate; OddsPath < 1/2.0 = supporting).
    * **Internal Decision Logic (Typical Outcomes):**
        * For PS3 (Pathogenic):
            * OddsPath very high (e.g., > 18.7): **PS3_very_strong**
            * OddsPath moderate (e.g., > 4.3 and <= 18.7): **PS3_moderate**
            * OddsPath supporting (e.g., > 2.0 and <= 4.3): **PS3_supporting**
        * For BS3 (Benign):
            * OddsPath very low (e.g., < 1/18.7): **BS3_very_strong**
            * OddsPath moderate (e.g., < 1/4.3 and >= 1/18.7): **BS3_moderate**
            * OddsPath supporting (e.g., < 1/2.0 and >= 1/4.3): **BS3_supporting**


Answer:
```json
{
  "functional_evidence_assessment": []
}
```

```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "C",
          "alt": "G",
          "position": "289"
        },
        "variant_string_id": "Parkin C289G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Cells were treated with CCCP and immunolabeled with anti-Hsp60 to assess mitochondrial function.",
          "judgment": "Yes",
          "reasoning": "The paper defines a disease mechanism related to mitochondrial dysfunction, which is relevant to the Parkin gene's role in mitophagy."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The percentage of cells with overlapping GFP-LC3 and MitoDsRed staining was quantified in cells co-transfected with FLAG-Parkin(WT) and FLAG-Parkin(C289G).",
          "judgment": "Yes",
          "reasoning": "The assay used (quantification of overlapping GFP-LC3 and MitoDsRed staining) is applicable to the disease mechanism as it measures mitophagy, a key function of Parkin.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Experiments were performed with multiple replicates and included both wild-type (FLAG-Parkin(WT)) and mutant (FLAG-Parkin(C289G)) controls.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that multiple replicates were used and includes both wild-type and mutant controls, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study used FLAG-Parkin(WT) as a normal control and FLAG-Parkin(C289G) as the variant of interest.",
          "judgment": "No",
          "reasoning": "The study lacks additional variant controls such as known pathogenic or benign variants, limiting the ability to compare the variant of interest.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study quantifies the incidence of transfected cells with mitochondrial staining in CCCP-treated cells but does not calculate OddsPath.",
          "judgment": "N/A",
          "reasoning": "The study does not provide a statistical analysis sufficient for OddsPath calculation and uses fewer than 10 variant controls.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The Parkin C289G variant shows a functional impact on mitophagy, but the evidence is limited to supporting strength due to insufficient variant controls and lack of statistical analysis for OddsPath."
    }
  ]
}
```

**Note**: The provided answer assumes that the functional evidence aims to demonstrate pathogenicity based on the context of mitophagy dysfunction associated with Parkin mutations. The strength of the evidence was determined as "PS3_supporting" due to the lack of variant controls and statistical analysis for OddsPath.
Based on the text provided, I've extracted information about the Parkin C289G variant and applied the ACMG functional evidence evaluation flowchart.

The assessment concludes that the Parkin C289G variant has functional evidence supporting pathogenicity with a strength of PS3_supporting. This assessment is based on:
1. The clear disease mechanism defined (mitochondrial dysfunction)
2. Appropriate assay used (quantification of overlapping GFP-LC3 and MitoDsRed staining to measure mitophagy)
3. Sufficient basic controls and replicates
4. Limitations in variant controls (only wild-type and the variant of interest, no additional known pathogenic or benign variants)
5. Lack of statistical analysis for OddsPath calculation

This assessment aligns with the ACMG guidelines for functional evidence evaluation.

ed with CCCP (20 mM, 4 h) and immunolabeled with anti-Hsp60 (red). (B) The percentage of cells with overlapping GFP-LC3 and MitoDsRed staining was quantified in cells co-transfected with FLAG-Parkin(WT), FLAG-Parkin(C289G) + myc-HSJ1a(WT) and treated with CCCP (20 mM, 4 h). Error bars: +2 SE, n ¼ 4, * * * P , 0.001. (C) Quantification of the incide

 bars: +2 SE, n ¼ 4, * * * P , 0.001. (C) Quantification of the incidence of transfected cells with mitochondrial staining in cells treated with CCCP (20 mM, 24 h, left bar), CCCP + 3-MA (10 mM, 24 h, right bar). Error bars: +2 SE, n ¼ 4, * P , 0.5.

in and 100 mg/ml streptomycin (Invitrogen). Cells were grown at 378C in 5% (v/v) CO 2 . Transfections using a constant amount of plasmid DNA were performed using Lipofectamine TM and PLUS TM reagents (Invitrogen), according to the manufacturer's protocol.

##Antibodies and reagents
Mouse monoclonal anti-FLAG (M2), mouse monoclonal anti-Hsp60 (LK1) 

Question:

**Instruction:**
You are a highly skilled scientific text analysis and gene variant assessment assistant. Your primary task is to:
1.  **Extract relevant functional evidence details** from the provided scientific paper text for *each variant* mentioned that has functional data.
2.  **Parse variant identification information** to populate the specific fields: "Gene", "Protein Change" (ref, alt, position), and a combined "variant\_string\_id".
3.  **Apply the ACMG functional evidence evaluation flowchart** to the extracted information for each variant.
4.  **Determine the strength of the functional evidence** (PS3 for pathogenic, BS3 for benign) for each variant.
5.  **Output the results in a pyJSON format**, including the step-by-step judgment process and the final strength rating for each variant.

**Output Format:**
Your final output MUST be a JSON object. The top-level key will be `functional_evidence_assessment`. Its value will be an array of objects, where each object represents the assessment for a single variant. Each variant object should have the following structure:

```json
{
  "variant_id": {
    "Gene": "Extracted_Gene_Symbol", // E.g., "EGFR", "CFTR"
    "Protein_Change": {
      "ref": "Extracted_Reference_Amino_Acid", // E.g., "L", "R"
      "alt": "Extracted_Alternate_Amino_Acid", // E.g., "R", "H"
      "position": "Extracted_Amino_Acid_Position" // E.g., "858", "117"
    },
    "variant_string_id": "Gene RefPosAlt" // E.g., "EGFR L858R", "CFTR R117H"
  },
  "functional_evidence_aim": "Pathogenic", // or "Benign", derived from the paper's context of what the functional assay aims to show
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "Quote or concise summary of the relevant text from the paper.",
      "judgment": "Yes", // or "No"
      "reasoning": "Explanation based on extracted info and flowchart logic."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "Quote or concise summary of the relevant text from the paper.",
      "judgment": "Yes", // or "No"
      "reasoning": "Explanation based on extracted info and flowchart logic.",
      "next_step_or_outcome": "Proceed to Step 3" // or "Do not use PS3/BS3"
    }
    // ... (Include all relevant sub-steps taken according to the flowchart,
    //     each with "step_name", "extracted_paper_info", "judgment", "reasoning", and "next_step_or_outcome" if applicable)
  ],
  "final_evidence_strength": {
    "type": "Pathogenic", // or "Benign"
    "strength": "PS3_very_strong" // or "PS3_moderate", "PS3_supporting", "BS3_very_strong", "BS3_moderate", "BS3_supporting", "N/A" if "Do not use PS3/BS3"
  },
  "overall_conclusion": "Brief summary of why this strength was assigned for this variant, referencing key findings."
}
```

**ACMG Functional Evidence Evaluation Flowchart (Reference Standard for LLM's Internal Logic):**

**Step 1: Define the disease mechanism.**
* **Internal Question:** Does the paper clearly define the disease mechanism relevant to the functional assay being described for this variant?
* **Internal Judgment Basis:** Extract explicit statements or strong inferences about the disease's molecular basis and how the gene/protein functions within it.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Question:** Does the *general class* of assay used for this variant (e.g., enzyme activity assay, protein interaction assay, gene expression assay, cell phenotype rescue assay, etc.) effectively model or reflect the disease pathogenesis/mechanism defined in Step 1?
* **Internal Decision Logic:**
    * If **NO**: Then **Do not use PS3/BS3**. (Functional evidence not applicable).
    * If **YES**: Proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Question 1:** Were basic controls included for this assay? Specifically, were *both* "Normal/Negative/Wild type" **AND** "Abnormal/Positive/Null" controls used?
    * **Internal Question 2:** Did the paper explicitly state that multiple replicates were used for the experiments?
    * **Internal Judgment Basis:** Search "Materials and Methods" and "Results" for descriptions of controls (e.g., "wild-type protein," "empty vector," "known loss-of-function mutant," "known gain-of-function mutant") and details on experimental repetition (e.g., "performed in triplicate," "n=3 independent experiments").
    * **Internal Decision Logic (for 3a):**
        * If **NO** (either condition not met): Proceed to Sub-step 3b.
        * If **YES** (both conditions met): Proceed to Sub-step 3c.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Question:** Has the specific instance of the assay been:
        * a) Broadly accepted historically (e.g., standard technique in the field)? **OR**
        * b) Previously validated in other studies (cited)? **OR**
        * c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?
    * **Internal Judgment Basis:** Look for statements on assay novelty, references to prior validation, or mentions of commercial kits/standards.
    * **Internal Decision Logic (for 3b):**
        * If **NO** (all conditions not met): Then **Do not use PS3/BS3**.
        * If **YES** (any condition met): The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Question:** Were variant controls used in the assay for this variant? Specifically, were:
        * Known pathogenic variants used as controls? **OR**
        * Known benign variants used as controls? **OR**
        * Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?
    * **Internal Judgment Basis:** Identify lists of variants used as positive/negative controls and their stated classifications or known status.
    * **Internal Decision Logic (for 3c):**
        * If **NO** (all conditions not met): The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.
        * If **YES** (any condition met): Proceed to Step 4.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Question:** Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays).
    * **Internal Judgment Basis:** Look for mentions of statistical tests, p-values, effect sizes, confidence intervals, or direct calculation/reporting of OddsPath.
    * **Internal Decision Logic (for 4a):**
        * If **NO**: Proceed to Sub-step 4b.
        * If **YES**: Proceed to Sub-step 4c.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Question:** How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?
    * **Internal Judgment Basis:** Count the number of explicitly identified benign and pathogenic control variants used in the assays related to this variant.
    * **Internal Decision Logic (for 4b):**
        * If **10 or less** in total: The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.
        * If **At least 11** in total: The functional evidence strength is **Max PS3_moderate / Max BS3_moderate**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Information:** Extract the OddsPath value calculated in the paper for this variant. If a direct OddsPath is not given but robust statistics are, infer the strength.
    * **Internal Judgment Basis:** Apply ACMG guidelines for OddsPath interpretation (e.g., assuming standard thresholds: PS3: OddsPath > 18.7 = very_strong; OddsPath > 4.3 = moderate; OddsPath > 2.0 = supporting. BS3: OddsPath < 1/18.7 = very_strong; OddsPath < 1/4.3 = moderate; OddsPath < 1/2.0 = supporting).
    * **Internal Decision Logic (Typical Outcomes):**
        * For PS3 (Pathogenic):
            * OddsPath very high (e.g., > 18.7): **PS3_very_strong**
            * OddsPath moderate (e.g., > 4.3 and <= 18.7): **PS3_moderate**
            * OddsPath supporting (e.g., > 2.0 and <= 4.3): **PS3_supporting**
        * For BS3 (Benign):
            * OddsPath very low (e.g., < 1/18.7): **BS3_very_strong**
            * OddsPath moderate (e.g., < 1/4.3 and >= 1/18.7): **BS3_moderate**
            * OddsPath supporting (e.g., < 1/2.0 and >= 1/4.3): **BS3_supporting**


Answer:
```json
{
  "functional_evidence_assessment": []
}
```

```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "C",
          "alt": "G",
          "position": "289"
        },
        "variant_string_id": "Parkin C289G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Cells were treated with CCCP and immunolabeled with anti-Hsp60 to assess mitochondrial function.",
          "judgment": "Yes",
          "reasoning": "The paper defines a disease mechanism related to mitochondrial dysfunction, which is relevant to the Parkin gene's role in mitophagy."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The percentage of cells with overlapping GFP-LC3 and MitoDsRed staining was quantified in cells co-transfected with FLAG-Parkin(WT) and FLAG-Parkin(C289G).",
          "judgment": "Yes",
          "reasoning": "The assay used (quantification of overlapping GFP-LC3 and MitoDsRed staining) is applicable to the disease mechanism as it measures mitophagy, a key function of Parkin.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Experiments were performed with multiple replicates and included both wild-type (FLAG-Parkin(WT)) and mutant (FLAG-Parkin(C289G)) controls.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that multiple replicates were used and includes both wild-type and mutant controls, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study used FLAG-Parkin(WT) as a normal control and FLAG-Parkin(C289G) as the variant of interest.",
          "judgment": "No",
          "reasoning": "The study lacks additional variant controls such as known pathogenic or benign variants, limiting the ability to compare the variant of interest.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study quantifies the incidence of transfected cells with mitochondrial staining in CCCP-treated cells but does not calculate OddsPath.",
          "judgment": "N/A",
          "reasoning": "The study does not provide a statistical analysis sufficient for OddsPath calculation and uses fewer than 10 variant controls.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The Parkin C289G variant shows a functional impact on mitophagy, but the evidence is limited to supporting strength due to insufficient variant controls and lack of statistical analysis for OddsPath."
    }
  ]
}
```

**Note**: The provided answer assumes that the functional evidence aims to demonstrate pathogenicity based on the context of mitophagy dysfunction associated with Parkin mutations. The strength of the evidence was determined as "PS3_supporting" due to the lack of variant controls and statistical analysis for OddsPath.
Based on the text provided, I've extracted information about the Parkin C289G variant and applied the ACMG functional evidence evaluation flowchart.

The assessment concludes that the Parkin C289G variant has functional evidence supporting pathogenicity with a strength of PS3_supporting. This assessment is based on:
1. The clear disease mechanism defined (mitochondrial dysfunction)
2. Appropriate assay used (quantification of overlapping GFP-LC3 and MitoDsRed staining to measure mitophagy)
3. Sufficient basic controls and replicates
4. Limitations in variant controls (only wild-type and the variant of interest, no additional known pathogenic or benign variants)
5. Lack of statistical analysis for OddsPath calculation

This assessment aligns with the ACMG guidelines for functional evidence evaluation.

ed with CCCP (20 mM, 4 h) and immunolabeled with anti-Hsp60 (red). (B) The percentage of cells with overlapping GFP-LC3 and MitoDsRed staining was quantified in cells co-transfected with FLAG-Parkin(WT), FLAG-Parkin(C289G) + myc-HSJ1a(WT) and treated with CCCP (20 mM, 4 h). Error bars: +2 SE, n ¼ 4, * * * P , 0.001. (C) Quantification of the incide

 bars: +2 SE, n ¼ 4, * * * P , 0.001. (C) Quantification of the incidence of transfected cells with mitochondrial staining in cells treated with CCCP (20 mM, 24 h, left bar), CCCP + 3-MA (10 mM, 24 h, right bar). Error bars: +2 SE, n ¼ 4, * P , 0.5.

in and 100 mg/ml streptomycin (Invitrogen). Cells were grown at 378C in 5% (v/v) CO 2 . Transfections using a constant amount of plasmid DNA were performed using Lipofectamine TM and PLUS TM reagents (Invitrogen), according to the manufacturer's protocol.

##Antibodies and reagents
Mouse monoclonal anti-FLAG (M2), mouse monoclonal anti-Hsp60 (LK1) 

Question:

**Instruction:**
You are a highly skilled scientific text analysis and gene variant assessment assistant. Your primary task is to:
1.  **Extract relevant functional evidence details** from the provided scientific paper text for *each variant* mentioned that has functional data.
2.  **Parse variant identification information** to populate the specific fields: "Gene", "Protein Change" (ref, alt, position), and a combined "variant\_string\_id".
3.  **Apply the ACMG functional evidence evaluation flowchart** to the extracted information for each variant.
4.  **Determine the strength of the functional evidence** (PS3 for pathogenic, BS3 for benign) for each variant.
5.  **Output the results in a pyJSON format**, including the step-by-step judgment process and the final strength rating for each variant.

**Output Format:**
Your final output MUST be a JSON object. The top-level key will be `functional_evidence_assessment`. Its value will be an array of objects, where each object represents the assessment for a single variant. Each variant object should have the following structure:

```json
{
  "variant_id": {
    "Gene": "Extracted_Gene_Symbol", // E.g., "EGFR", "CFTR"
    "Protein_Change": {
      "ref": "Extracted_Reference_Amino_Acid", // E.g., "L", "R"
      "alt": "Extracted_Alternate_Amino_Acid", // E.g., "R", "H"
      "position": "Extracted_Amino_Acid_Position" // E.g., "858", "117"
    },
    "variant_string_id": "Gene RefPosAlt" // E.g., "EGFR L858R", "CFTR R117H"
  },
  "functional_evidence_aim": "Pathogenic", // or "Benign", derived from the paper's context of what the functional assay aims to show
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "Quote or concise summary of the relevant text from the paper.",
      "judgment": "Yes", // or "No"
      "reasoning": "Explanation based on extracted info and flowchart logic."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "Quote or concise summary of the relevant text from the paper.",
      "judgment": "Yes", // or "No"
      "reasoning": "Explanation based on extracted info and flowchart logic.",
      "next_step_or_outcome": "Proceed to Step 3" // or "Do not use PS3/BS3"
    }
    // ... (Include all relevant sub-steps taken according to the flowchart,
    //     each with "step_name", "extracted_paper_info", "judgment", "reasoning", and "next_step_or_outcome" if applicable)
  ],
  "final_evidence_strength": {
    "type": "Pathogenic", // or "Benign"
    "strength": "PS3_very_strong" // or "PS3_moderate", "PS3_supporting", "BS3_very_strong", "BS3_moderate", "BS3_supporting", "N/A" if "Do not use PS3/BS3"
  },
  "overall_conclusion": "Brief summary of why this strength was assigned for this variant, referencing key findings."
}
```

**ACMG Functional Evidence Evaluation Flowchart (Reference Standard for LLM's Internal Logic):**

**Step 1: Define the disease mechanism.**
* **Internal Question:** Does the paper clearly define the disease mechanism relevant to the functional assay being described for this variant?
* **Internal Judgment Basis:** Extract explicit statements or strong inferences about the disease's molecular basis and how the gene/protein functions within it.

**Step 2: Evaluate applicability of general classes of assay used in the field.**
* **Internal Question:** Does the *general class* of assay used for this variant (e.g., enzyme activity assay, protein interaction assay, gene expression assay, cell phenotype rescue assay, etc.) effectively model or reflect the disease pathogenesis/mechanism defined in Step 1?
* **Internal Decision Logic:**
    * If **NO**: Then **Do not use PS3/BS3**. (Functional evidence not applicable).
    * If **YES**: Proceed to Step 3.

**Step 3: Evaluate validity of specific instances of assays.**
* **Sub-step 3a: Basic Controls and Replicates.**
    * **Internal Question 1:** Were basic controls included for this assay? Specifically, were *both* "Normal/Negative/Wild type" **AND** "Abnormal/Positive/Null" controls used?
    * **Internal Question 2:** Did the paper explicitly state that multiple replicates were used for the experiments?
    * **Internal Judgment Basis:** Search "Materials and Methods" and "Results" for descriptions of controls (e.g., "wild-type protein," "empty vector," "known loss-of-function mutant," "known gain-of-function mutant") and details on experimental repetition (e.g., "performed in triplicate," "n=3 independent experiments").
    * **Internal Decision Logic (for 3a):**
        * If **NO** (either condition not met): Proceed to Sub-step 3b.
        * If **YES** (both conditions met): Proceed to Sub-step 3c.

* **Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).**
    * **Internal Question:** Has the specific instance of the assay been:
        * a) Broadly accepted historically (e.g., standard technique in the field)? **OR**
        * b) Previously validated in other studies (cited)? **OR**
        * c) Provided as a commercial kit with defined performance metrics, *but* where controls/replicates are not documented for the specific instance of the assay in *this* paper?
    * **Internal Judgment Basis:** Look for statements on assay novelty, references to prior validation, or mentions of commercial kits/standards.
    * **Internal Decision Logic (for 3b):**
        * If **NO** (all conditions not met): Then **Do not use PS3/BS3**.
        * If **YES** (any condition met): The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.

* **Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a).**
    * **Internal Question:** Were variant controls used in the assay for this variant? Specifically, were:
        * Known pathogenic variants used as controls? **OR**
        * Known benign variants used as controls? **OR**
        * Were variants tested that reach P/LP (Pathogenic/Likely Pathogenic) or B/LB (Benign/Likely Benign) criteria *without* relying on PS3/BS3 evidence themselves?
    * **Internal Judgment Basis:** Identify lists of variants used as positive/negative controls and their stated classifications or known status.
    * **Internal Decision Logic (for 3c):**
        * If **NO** (all conditions not met): The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.
        * If **YES** (any condition met): Proceed to Step 4.

**Step 4: Apply evidence to individual variant interpretation.**
* **Sub-step 4a: Statistical Analyses.**
    * **Internal Question:** Are the statistical analyses in the paper sufficient to estimate or calculate OddsPath for the functional data for this variant? (OddsPath refers to a quantitative measure of pathogenicity likelihood from functional assays).
    * **Internal Judgment Basis:** Look for mentions of statistical tests, p-values, effect sizes, confidence intervals, or direct calculation/reporting of OddsPath.
    * **Internal Decision Logic (for 4a):**
        * If **NO**: Proceed to Sub-step 4b.
        * If **YES**: Proceed to Sub-step 4c.

* **Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient).**
    * **Internal Question:** How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?
    * **Internal Judgment Basis:** Count the number of explicitly identified benign and pathogenic control variants used in the assays related to this variant.
    * **Internal Decision Logic (for 4b):**
        * If **10 or less** in total: The functional evidence strength is **Max PS3_supporting / Max BS3_supporting**.
        * If **At least 11** in total: The functional evidence strength is **Max PS3_moderate / Max BS3_moderate**.

* **Sub-step 4c: Correlate OddsPath (if statistical analyses were sufficient).**
    * **Internal Information:** Extract the OddsPath value calculated in the paper for this variant. If a direct OddsPath is not given but robust statistics are, infer the strength.
    * **Internal Judgment Basis:** Apply ACMG guidelines for OddsPath interpretation (e.g., assuming standard thresholds: PS3: OddsPath > 18.7 = very_strong; OddsPath > 4.3 = moderate; OddsPath > 2.0 = supporting. BS3: OddsPath < 1/18.7 = very_strong; OddsPath < 1/4.3 = moderate; OddsPath < 1/2.0 = supporting).
    * **Internal Decision Logic (Typical Outcomes):**
        * For PS3 (Pathogenic):
            * OddsPath very high (e.g., > 18.7): **PS3_very_strong**
            * OddsPath moderate (e.g., > 4.3 and <= 18.7): **PS3_moderate**
            * OddsPath supporting (e.g., > 2.0 and <= 4.3): **PS3_supporting**
        * For BS3 (Benign):
            * OddsPath very low (e.g., < 1/18.7): **BS3_very_strong**
            * OddsPath moderate (e.g., < 1/4.3 and >= 1/18.7): **BS3_moderate**
            * OddsPath supporting (e.g., < 1/2.0 and >= 1/4.3): **BS3_supporting**


Answer:
```json
{
  "functional_evidence_assessment": []
}
```

```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "C",
          "alt": "G",
          "position": "289"
        },
        "variant_string_id": "Parkin C289G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Cells were treated with CCCP and immunolabeled with anti-Hsp60 to assess mitochondrial function.",
          "judgment": "Yes",
          "reasoning": "The paper defines a disease mechanism related to mitochondrial dysfunction, which is relevant to the Parkin gene's role in mitophagy."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The percentage of cells with overlapping GFP-LC3 and MitoDsRed staining was quantified in cells co-transfected with FLAG-Parkin(WT) and FLAG-Parkin(C289G).",
          "judgment": "Yes",
          "reasoning": "The assay used (quantification of overlapping GFP-LC3 and MitoDsRed staining) is applicable to the disease mechanism as it measures mitophagy, a key function of Parkin.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Experiments were performed with multiple replicates and included both wild-type (FLAG-Parkin(WT)) and mutant (FLAG-Parkin(C289G)) controls.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that multiple replicates were used and includes both wild-type and mutant controls, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study used FLAG-Parkin(WT) as a normal control and FLAG-Parkin(C289G) as the variant of interest.",
          "judgment": "No",
          "reasoning": "The study lacks additional variant controls such as known pathogenic or benign variants, limiting the ability to compare the variant of interest.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study quantifies the incidence of transfected cells with mitochondrial staining in CCCP-treated cells but does not calculate OddsPath.",
          "judgment": "N/A",
          "reasoning": "The study does not provide a statistical analysis sufficient for OddsPath calculation and uses fewer than 10 variant controls.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The Parkin C289G variant shows a functional impact on mitophagy, but the evidence is limited to supporting strength due to insufficient variant controls and lack of statistical analysis for OddsPath."
    }
  ]
}
```

**Note**: The provided answer assumes that the functional evidence aims to demonstrate pathogenicity based on the context of mitophagy dysfunction associated with Parkin mutations. The strength of the evidence was determined as "PS3_supporting" due to the lack of variant controls and statistical analysis for OddsPath.
Based on the text provided, I've extracted information about the Parkin C289G variant and applied the ACMG functional evidence evaluation flowchart.

The assessment concludes that the Parkin C289G variant has functional evidence supporting pathogenicity with a strength of PS3_supporting. This assessment is based on:
1. The clear disease mechanism defined (mitochondrial dysfunction)
2. Appropriate assay used (quantification of overlapping GFP-LC3 and MitoDsRed staining to measure mitophagy)
3. Sufficient basic controls and replicates
4. Limitations in variant controls (only wild-type and the variant of interest, no additional known pathogenic or benign variants)
5. Lack of statistical analysis for OddsPath calculation

This assessment aligns with the ACMG guidelines for functional evidence evaluation.

ed with CCCP (20 mM, 4 h) and immunolabeled with anti-Hsp60 (red). (B) The percentage of cells with overlapping GFP-LC3 and MitoDsRed staining was quantified in cells co-transfected with FLAG-Parkin(WT), FLAG-Parkin(C289G) + myc-HSJ1a(WT) and treated with CCCP (20 mM, 4 h). Error bars: +2 SE, n ¼ 4, * * * P , 0.001. (C) Quantification of the incide

 bars: +2 SE, n ¼ 4, * * * P , 0.001. (C) Quantification of the incidence of transfected cells with mitochondrial staining in cells treated with CCCP (20 mM, 24 h, left bar), CCCP + 3-MA (10 mM, 24 h, right bar). Error bars: +2 SE, n ¼ 4, * P , 0.5.

in and 100 mg/ml streptomycin (Invitrogen). Cells were grown at 378C in 5% (v/v) CO 2 . Transfections using a constant amount of plasmid DNA were performed using Lipofectamine TM and PLUS TM reagents (Invitrogen), according to the manufacturer's protocol.

##Antibodies and reagents
Mouse monoclonal anti-FLAG (M2), mouse monoclonal anti-Hsp60 (LK1) 

Question:

**Instruction:**
You are a highly skilled scientific text analysis and gene variant assessment assistant. Your primary task is to:
1.  **Extract relevant functional evidence details** from the provided scientific paper text for *each variant* mentioned that has functional data.
2.  **Parse variant identification information** to populate the specific fields: "Gene", "Protein Change" (ref, alt, position), and a combined "variant\_string\_id".
3.  **Apply the ACMG functional evidence evaluation flowchart** to the extracted information for each variant.
4.  **Determine the strength of the functional evidence** (PS3 for pathogenic, BS3 for benign) for each variant.
5.  **Output the results in a pyJSON format**, including the step-by-step judgment process and the final strength rating for each variant.

**Output Format:**
Your final output MUST be a JSON object. The top-level key will be `functional_evidence_assessment`. Its value will be an array of